Ampio Pharmaceuticals has reported that its AP-014 Phase I clinical trial of inhaled drug Ampion showed a 78% improvement in all-cause mortality in Covid-19 patients with respiratory distress.

All trial subjects have completed treatment, including a 28-day follow-up on receiving the drug.

Results showed that the study did not met its primary endpoint while Ampion caused better improvement in all-cause mortality as compared to subjects treated with Standard of Care (SOC) than reported in the initial stage.

According to the final data from the Phase I trial, mortality in the SOC group was 24% as against 5% in the group receiving SOC plus Ampion. Preliminary results, which were reported in March, showed a 21% mortality rate for SOC versus 8% for Ampion indicating a 62% improvement.

Furthermore, subjects who received Ampion needed reduced hospitalisation time and the average hospital length of stay was four days less as against those receiving SOC.

By day five, 89% of subjects in the Ampion group were stable or showed improvement versus 77% in the SOC group.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Treatment with Ampion was safe and well-tolerated in all trial subjects with no remarkable adverse events related to the drug reported.

Ampio president and CEO Michael Macaluso said: “These are strong results from a Phase I trial, and we are looking forward to continuing immediately with the commencement of our double-blind placebo-controlled Phase II trials utilizing Ampion in both in an inhaled form for Covid-19 respiratory distress and intravenously for more systemic symptoms of Covid-19.

“If these Phase II studies confirm the efficacy results seen in our Phase I trials, I can envision moving forward quickly with an application for Emergency Use Authorization (EUA) for Ampion in treating Covid-19.”

Last month, Ampio revealed preliminary positive results of its AP-014 Phase I trial that involved using inhaled Ampion in treating respiratory distress in patients due to Covid-19.

Meanwhile, the company also received a positive response from the US Food and Drug Administration (FDA) to commence its AP-013 Phase III trial of intra-articular injection of Ampion for treating osteoarthritis of the knee.

This trial was paused last year owing to the Covid-19 pandemic situation.